| Project/Area Number |
25660240
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Veterinary medical science
|
|---|
| Research Institution | Tottori University |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
ARITA Shinji
ARITA Noboru
MIYATAKE Marina
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | 肺高血圧症 / 僧帽弁閉鎖不全症 / 血管リモデリング / イマチニブ / 慢性心不全 / イヌ / ラット / スニチニブ / 血小板由来因子 / PDGF受容体 / 犬 |
|---|
| Outline of Final Research Achievements |
This study was conducted to examine the efficacy of molecular target drugs having inhibitory activity of platelet-derived growth factor for pulmonary hypertension (PH) caused by chronic heart failure in dogs. For this purpose, the depression effect of the pulmonary blood vessel remodeling and the improvement effect of the right ventricular hypertrophy of molecular target drugs including imatinib were examined in the PH rat model. As a result, it was suggested that imatinib and sunitinib improved PH through the suppression of the pulmonary vascular remodeling. Subsequently, the efficacy of the low-dose imatinib therapy for the pulmonary hypertension caused by chronic heart failure in dogs was evaluated on clinical signs and various circulation parameters. As a result, the therapy with low-dose imatinib significantly improved PH and heart failure. Therefore, imatinib is useful as a therapeutic drug for the PH caused by the chronic heart failure in dogs.
|
